Tocilizumab for multirefractory adult-onset Still's disease

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 153-154

  De Bandt, M ^a   Saint Marcoux, B ^a  

^a R Ballanger Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; CYCLOSPORIN A; ETANERCEPT; GOLD; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; THALIDOMIDE;

ADULT; ADULT ONSET STILL DISEASE; ARTHRITIS; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; LABORATORY TEST; LETTER; LEUKOCYTE COUNT; LYMPHADENOPATHY; PRIORITY JOURNAL; RASH; SPLENOMEGALY; THERAPY EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; FEMALE; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; STILL'S DISEASE, ADULT-ONSET;

EID: 58349119558     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.088179     Document Type: Letter

References (10)

1. Efthimiou P. Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 2007; 3:328-35.
2. Saiki O, Uda H, Nishimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still's disease reflects a Th2 rather than a Th1 cytokine profile. Clin Immunol 2004; 112:120-5.
3. Fautrel B, Sibilia J, Mariette X, Combe B. Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005; 64:262-6.
4. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis 2006; 65:1117-8.
5. Lequerré T, Quarter P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease. Preliminary experience in France. Ann Rheum Dis 2008; 67:302-8.
6. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 2007; 30:2001-6.
7. Genovese M, McKay J, Nasonov E, Mysler E, da Silva N, Alecock E, et al. IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: the TOWARD Study [abstract]. Arthritis Rheum 2007;56(suppl 9).
8. Smolen J, Beaulieu A, Rubbert-Roth A, Alecock E, Alten R, Woodworth T. Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2007; 66(Suppl 11):87.
9. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66:1162-7.
10. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7:R1281-8.